Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on December 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard Lowenthal, the CEO of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on December 17, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions at weighted average prices of $11.6715 and $11.6705, with prices ranging from $11.56 to $11.95.
• Following the transactions, Lowenthal directly owns 4,327,189 shares.
• Lowenthal also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Richard Lowenthal Charitable Remainder UniTrust, as well as shares held by his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan. It doesn't inherently indicate positive or negative news about the company's performance.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price.

Industry Context

Sales by executives are a normal part of corporate governance, especially when executed under pre-arranged trading plans like Rule 10b5-1, which are designed to prevent accusations of insider trading.

Stakeholder Impact

• Shareholders may react to the news of the CEO selling shares, although the existence of a 10b5-1 plan mitigates potential concerns.

Key Dates